Mechanistic and Functional Extrapolation of SET and MYND Domain-containing Protein 2 to Pancreatic Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Sep 26

PMID 36157542

Authors

Eid Alshammari

Ying-Xue Zhang

Zhe Yang

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal neoplasms worldwide and represents the vast majority of pancreatic cancer cases. Understanding the molecular pathogenesis and the underlying mechanisms involved in the initiation, maintenance, and progression of PDAC is an urgent need, which may lead to the development of novel therapeutic strategies against this deadly cancer. Here, we review the role of SET and MYND domain-containing protein 2 (SMYD2) in initiating and maintaining PDAC development through methylating multiple tumor suppressors and oncogenic proteins. Given the broad substrate specificity of SMYD2 and its involvement in diverse oncogenic signaling pathways in many other cancers, the mechanistic extrapolation of SMYD2 from these cancers to PDAC may allow for developing new hypotheses about the mechanisms driving PDAC tumor growth and metastasis, supporting a proposition that targeting SMYD2 could be a powerful strategy for the prevention and treatment of PDAC.

Citing Articles

Structure of the SMYD2-PARP1 Complex Reveals Both Productive and Allosteric Modes of Peptide Binding.

Zhang Y, Alshammari E, Sobota J, Spellmon N, Perry E, Cao T bioRxiv. 2024; .

PMID: 39677743 PMC: 11642878. DOI: 10.1101/2024.12.03.626679.

References

Zeng Y, Qiu R, Yang Y, Gao T, Zheng Y, Huang W . Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis. Cell Rep. 2019; 29(6):1482-1498.e4. DOI: 10.1016/j.celrep.2019.10.004. View

Patil S, Forster T, Reutlinger K, Kopp W, Versemann L, Spitalieri J . Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. Cells. 2021; 10(12). PMC: 8700089. DOI: 10.3390/cells10123463. View

Huang C, Xie K . Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev. 2012; 23(1-2):25-35. PMC: 3307878. DOI: 10.1016/j.cytogfr.2012.01.003. View

Ferguson A, Larsen N, Howard T, Pollard H, Green I, Grande C . Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011; 19(9):1262-73. DOI: 10.1016/j.str.2011.06.011. View

Yi X, Jiang X, Fang Z . Histone methyltransferase SMYD2: ubiquitous regulator of disease. Clin Epigenetics. 2019; 11(1):112. PMC: 6670139. DOI: 10.1186/s13148-019-0711-4. View

Cho H, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T . RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia. 2012; 14(6):476-86. PMC: 3394190. DOI: 10.1593/neo.12656. View

Yue H, Na Y, Feng X, Ma S, Song F, Yang B . Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer. World J Gastroenterol. 2003; 9(2):377-80. PMC: 4611351. DOI: 10.3748/wjg.v9.i2.377. View

Yu H, Zhang D, Lian M . Identification of an epigenetic prognostic signature for patients with lower-grade gliomas. CNS Neurosci Ther. 2021; 27(4):470-483. PMC: 7941239. DOI: 10.1111/cns.13587. View

Zhang Q, Li X, Li Y, Chen S, Shen X, Dong X . Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression. Invest New Drugs. 2019; 38(2):321-328. DOI: 10.1007/s10637-019-00791-7. View

10.

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

11.

Tront J, Hoffman B, Liebermann D . Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res. 2006; 66(17):8448-54. DOI: 10.1158/0008-5472.CAN-06-2013. View

12.

Reynoird N, Mazur P, Stellfeld T, Flores N, Lofgren S, Carlson S . Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev. 2016; 30(7):772-85. PMC: 4826394. DOI: 10.1101/gad.275529.115. View

13.

Blanco-Aparicio C, Renner O, Leal J, Carnero A . PTEN, more than the AKT pathway. Carcinogenesis. 2007; 28(7):1379-86. DOI: 10.1093/carcin/bgm052. View

14.

Kennedy A, Adams P, Morton J . Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy. Small GTPases. 2012; 2(5):264-267. PMC: 3265817. DOI: 10.4161/sgtp.2.5.17367. View

15.

Pires-Luis A, Vieira-Coimbra M, Vieira F, Costa-Pinheiro P, Silva-Santos R, Dias P . Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication. Epigenetics. 2015; 10(11):1033-43. PMC: 4844211. DOI: 10.1080/15592294.2015.1103578. View

16.

Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R . Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN. Neoplasia. 2015; 17(4):367-73. PMC: 4415136. DOI: 10.1016/j.neo.2015.03.002. View

17.

Wu L, Kou F, Ji Z, Li B, Zhang B, Guo Y . SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7. Cell Death Dis. 2021; 12(5):439. PMC: 8089105. DOI: 10.1038/s41419-021-03720-w. View

18.

Xu W, Chen F, Fei X, Yang X, Lu X . Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma. Med Sci Monit. 2018; 24:7357-7365. PMC: 6198713. DOI: 10.12659/MSM.910168. View

19.

Ronkina N, Menon M, Schwermann J, Tiedje C, Hitti E, Kotlyarov A . MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol. 2010; 80(12):1915-20. DOI: 10.1016/j.bcp.2010.06.021. View

20.

Saddic L, West L, Aslanian A, Yates 3rd J, Rubin S, Gozani O . Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 2010; 285(48):37733-40. PMC: 2988378. DOI: 10.1074/jbc.M110.137612. View